We have shown in cell lines and primary human AML blasts that oncogenic FLT3 signaling significantly suppresses PP2A activity, in association with decreased expression of the PP2A-A scaffolding and regulatory B subunits. The gene discussed is PPP2R1A; the disease is acute myeloid leukemia.